Versor Investments LP Buys New Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Versor Investments LP bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,210 shares of the company's stock, valued at approximately $549,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. LSV Asset Management lifted its stake in Harmony Biosciences by 346.5% during the 1st quarter. LSV Asset Management now owns 335,146 shares of the company's stock valued at $11,254,000 after acquiring an additional 260,093 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Harmony Biosciences by 9.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 319,167 shares of the company's stock worth $10,309,000 after purchasing an additional 28,256 shares during the period. Capital Management Corp VA bought a new position in shares of Harmony Biosciences in the 1st quarter worth approximately $7,018,000. Janus Henderson Group PLC lifted its stake in shares of Harmony Biosciences by 1,011.7% in the 1st quarter. Janus Henderson Group PLC now owns 185,083 shares of the company's stock worth $6,214,000 after purchasing an additional 168,434 shares during the period. Finally, Hedeker Wealth LLC bought a new position in shares of Harmony Biosciences in the 1st quarter worth approximately $2,627,000. Institutional investors own 86.23% of the company's stock.

Harmony Biosciences Price Performance

HRMY traded down $0.48 during trading on Thursday, reaching $35.56. 302,540 shares of the company traded hands, compared to its average volume of 373,437. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.09 and a current ratio of 3.13. Harmony Biosciences Holdings, Inc. has a 12-month low of $18.61 and a 12-month high of $39.26. The firm has a fifty day simple moving average of $33.81 and a 200 day simple moving average of $31.80. The company has a market cap of $2.02 billion, a P/E ratio of 15.43, a PEG ratio of 0.72 and a beta of 0.73.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.24. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The business had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. During the same period last year, the firm posted $0.56 EPS. The company's revenue was up 28.8% on a year-over-year basis. On average, equities analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HRMY shares. Citigroup started coverage on shares of Harmony Biosciences in a research note on Friday, June 21st. They issued a "buy" rating and a $48.00 price objective on the stock. Needham & Company LLC restated a "buy" rating and set a $52.00 target price on shares of Harmony Biosciences in a research note on Tuesday, August 6th. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $41.67.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.